What are the key difference for how Vazkepa will be marketed in EU vs Canada ? How big of a difference will these make, in your opinion please
If France, Italy, and Germany eventually approve a reimbursement plan then the EU market is about 10x Canada (equal+ to USA). Originally Canada had 5+ year revenue goals for Vascepa of 80-100MM dollars
Why will Vascepa sell in EU if Canada sales have been less than stellar
I really was hoping for big win in Canada that would give strong confidence for Europe reapplications